Combination therapy for advanced lung cancer with EGFR mutation
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study tests two medications together as a first treatment for advanced non-small cell lung cancer that has a certain EGFR mutation. The goal is to see if the combination can shrink tumors and control the cancer for a longer time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have advanced non-small cell lung cancer that cannot be removed by surgery and has a specific EGFR mutation (exon 19 deletion or L858R).
- You have not had any previous treatment for advanced lung cancer, though you may have had treatment for early-stage disease that came back more than 6 months later.
- You have at least one tumor that can be measured on scans.
- You are generally able to take care of yourself (ECOG 0 or 1).
- You have adequate organ function and are willing to use effective birth control if applicable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of two new drugs (JS212 and JS111) for advanced non-squamous lung cancer that has an EGFR gene mutation and has progressed despite previous EGFR-targeted therapy. The combination may help control the cancer better than standard treatments.
This trial tests a new drug called JS212 combined with other treatments for people with advanced or spreading lung cancer. It aims to see if the combination can help shrink tumors or slow the disease.
This trial tests a new drug (JS207) that targets both PD-1 and VEGF pathways, given alone or with other treatments, for people with advanced non-small cell lung cancer that has a specific gene change and has stopped responding to targeted therapy (TKI). The goal is to see if this combination can help shrink tumors or slow cancer growth.
This trial tests a new combination of drugs (JS212 plus another medicine) for people with advanced esophageal squamous cell carcinoma who have not had prior treatment. It aims to see if the combination is safe and effective.
This trial tests a new drug called JS212 for people with advanced solid tumors that have not responded to other treatments. The goal is to see if it is safe and if it can help shrink tumors.
This trial tests a new drug called JS212, given alone or with other medicines, for people with advanced triple-negative breast cancer that has not spread too much before. It aims to see if the drug can shrink tumors or slow the disease.
Hear when a new NSCLC Harboring EGFR Mutations trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.